International Life Sciences Chair Cheryl Reicin recently joined the Scrip
M&A Podcast to share insights on the evolving landscape of
biopharmaceutical mergers and acquisitions. In the episode, Cheryl
highlights an uptick in pre-M&A activity, as major
pharmaceutical companies increasingly leverage license and option
agreements to strengthen their pipelines and product portfolios
while positioning themselves for potential future
acquisitions.
Commenting on the current deal environment, Cheryl notes, “I
think we have to look at the whole ecosystem when we say it’s
not healthy. I think the pharmas want to reduce their risk in an
environment of some uncertainty, but they’re still planning
so that they have opportunities, and they’re putting a lot of
shots on goal right now so that they will have acquisitions in the
near future.”
Source